iBio, Inc.
IBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.02 | -0.98 | -0.29 |
| FCF Yield | -12.99% | -36.83% | -7.87% | -17.30% |
| EV / EBITDA | -3.40 | -1.54 | -8.31 | -4.81 |
| Quality | ||||
| ROIC | -10.15% | -28.27% | -34.09% | -25.65% |
| Gross Margin | -189.00% | 100.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 0.99 | 0.89 | 0.64 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | 115.44% | 736,706.30% | 83.19% | -41.37% |
| Free Cash Flow Growth | -23.42% | -48.00% | 19.41% | -4.17% |
| Safety | ||||
| Net Debt / EBITDA | 4.73 | 1.05 | 0.45 | 0.75 |
| Interest Coverage | -165.31 | -118.14 | -90.35 | -77.53 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -820.32 | 47.25 | 0.00 | 5.85 |